Sponsor

University of Michigan Rogel Cancer Center

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name University of Michigan Rogel Cancer Center appears in 106 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials106
Recruiting shown13
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerNCT06616155 · lead sponsor · 2026-06-01
RECRUITING
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS TrialNCT07443943 · lead sponsor · 2026-04-22
RECRUITING
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialNCT07158021 · lead sponsor · 2026-01-22
RECRUITING
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer PatientsNCT07291414 · lead sponsor · 2026-01-09
RECRUITING
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) TherapyNCT07096999 · lead sponsor · 2025-01-23
RECRUITING
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast CancerNCT06915168 · lead sponsor · 2024-11-13
RECRUITING
Gilteritinib for the Treatment of ALK NSCLCNCT06225427 · lead sponsor · 2024-07-25
RECRUITING
Breast Cancer Resiliency Through Exercise Program (B-REP)NCT06100263 · lead sponsor · 2024-05-28
RECRUITING
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast CancerNCT05996107 · lead sponsor · 2024-02-27
RECRUITING
Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic ProbeNCT05965180 · lead sponsor · 2023-10-16
RECRUITING
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With CancerNCT05183126 · lead sponsor · 2022-03-28
RECRUITING
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])NCT05038332 · lead sponsor · 2021-11-12
RECRUITING
Targeted Early Detection Program in Men at High Genetic Risk for Prostate CancerNCT07645391 · lead sponsor · 2017-01-01
RECRUITING
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE TrialNCT07526545 · lead sponsor · 2026-09-01
NOT_YET_RECRUITING
Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerNCT07682649 · lead sponsor · 2026-08-01
NOT_YET_RECRUITING
A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American FamiliesNCT07542405 · lead sponsor · 2026-06-15
NOT_YET_RECRUITING
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT TrialNCT06617455 · lead sponsor · 2024-10-31
TERMINATED
Multicenter Trial of ESK981 in Patients With Select Solid TumorsNCT05988918 · lead sponsor · 2024-04-19
ACTIVE_NOT_RECRUITING
Cardiac Rehabilitation to Improve Breast Cancer OutcomesNCT05867667 · lead sponsor · 2024-03-19
TERMINATED
Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast CancerNCT06228768 · lead sponsor · 2024-03-06
COMPLETED
Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot StudyNCT05764005 · lead sponsor · 2022-11-09
COMPLETED
Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision AidNCT05140252 · lead sponsor · 2022-05-12
COMPLETED
Michigan Genetic Hereditary Testing (MiGHT)NCT05162846 · lead sponsor · 2022-04-21
COMPLETED
Developing a Psychosexual Educational Partners Program: PEPP A Feasibility StudyNCT05070299 · lead sponsor · 2022-03-15
COMPLETED
An Attention-Restorative Therapy (ART)-Based Virtual Reality Intervention to Address Cancer-Related Cognitive Impairments Among Breast Cancer SurvivorsNCT05030792 · lead sponsor · 2021-10-26
COMPLETED
Lighting Intervention for Cancer-related FatigueNCT04827446 · lead sponsor · 2021-07-15
COMPLETED
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)NCT04748042 · lead sponsor · 2021-05-28
ACTIVE_NOT_RECRUITING
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerNCT04848337 · lead sponsor · 2021-05-25
ACTIVE_NOT_RECRUITING
Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer SurvivorsNCT04827459 · lead sponsor · 2021-05-12
COMPLETED
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated ArthralgiasNCT04754399 · lead sponsor · 2021-04-16
COMPLETED
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerNCT04703920 · lead sponsor · 2021-03-04
COMPLETED
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerNCT04194554 · lead sponsor · 2020-11-06
ACTIVE_NOT_RECRUITING
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate CancerNCT04396808 · lead sponsor · 2020-11-05
ACTIVE_NOT_RECRUITING
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate CancerNCT04272645 · lead sponsor · 2020-10-01
WITHDRAWN
Testing the Effect of Mindfulness for Prostatectomy OutcomesNCT04727710 · lead sponsor · 2020-08-26
TERMINATED
Altering Lipids for Tolerance of Aromatase Inhibitor TherapyNCT04268134 · lead sponsor · 2020-07-28
COMPLETED
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)NCT03787680 · lead sponsor · 2019-10-31
ACTIVE_NOT_RECRUITING
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate CancerNCT03300505 · lead sponsor · 2019-05-31
TERMINATED
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerNCT03559049 · lead sponsor · 2018-12-24
TERMINATED
Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsNCT03570619 · lead sponsor · 2018-12-14
COMPLETED
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)NCT03556904 · lead sponsor · 2018-12-10
COMPLETED
Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate CancerNCT03689582 · lead sponsor · 2018-11-13
TERMINATED
The ConnectedCancerCare Pilot Study (CCC)NCT03618017 · lead sponsor · 2018-08-08
COMPLETED
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung CancerNCT03228186 · lead sponsor · 2018-03-05
TERMINATED
Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted AgentsNCT03242915 · lead sponsor · 2017-10-03
COMPLETED
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to TrastuzumabNCT03135171 · lead sponsor · 2017-07-26
COMPLETED
Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate CancerNCT02946008 · lead sponsor · 2017-03-27
COMPLETED
Functional Imaging in Lung SBRTNCT03121300 · lead sponsor · 2017-02-06
COMPLETED
Genomics in Michigan Impacting Observation or RadiationNCT02783950 · lead sponsor · 2017-01-17
COMPLETED
Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast CancerNCT02712437 · lead sponsor · 2016-03-16
TERMINATED
Clinical Outcomes, Nutritional Status, Exercise and Psychosocial Factors in Pediatric Hematopoietic Cell TransplantNCT02734797 · lead sponsor · 2016-03-09
COMPLETED
A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung CancerNCT02492867 · lead sponsor · 2016-01-14
COMPLETED
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLCNCT02463994 · lead sponsor · 2015-10-01
COMPLETED
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver MutationsNCT02277457 · lead sponsor · 2015-09-01
WITHDRAWN
Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast RadiotherapyNCT02494453 · lead sponsor · 2015-06-01
COMPLETED
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)NCT02400190 · lead sponsor · 2015-05-27
ACTIVE_NOT_RECRUITING
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate CancerNCT02059213 · lead sponsor · 2014-06-01
COMPLETED
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer PatientsNCT02338115 · lead sponsor · 2014-05-01
COMPLETED
Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic PainNCT01912612 · lead sponsor · 2013-10-30
COMPLETED
Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast CancerNCT01975597 · lead sponsor · 2013-08-01
TERMINATED

Drugs studied in this sponsor's trials

54 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing University of Michigan Rogel Cancer Center as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
docetaxel7
carboplatin4
paclitaxel4
estramustine3
pembrolizumab3
anastrozole2
capecitabine2
duloxetine2
docetaxel RxCUI 72962 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials carboplatin RxCUI 40048 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials paclitaxel RxCUI 56946 · Lead sponsor in 4 linked trial(s) · 1 currently recruiting 4 trials estramustine RxCUI 4089 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials anastrozole RxCUI 84857 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials capecitabine RxCUI 194000 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials duloxetine RxCUI 72625 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials enzalutamide RxCUI 1307298 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials leuprolide RxCUI 42375 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials olaparib RxCUI 1597582 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials pemetrexed RxCUI 68446 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials trastuzumab RxCUI 224905 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials 20 ML atezolizumab 60 MG/ML Injection RxCUI 1792780 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial abemaciclib 150 MG RxCUI 1946841 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial abemaciclib 200 MG RxCUI 1946845 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial abiraterone RxCUI 1100072 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial abiraterone acetate RxCUI 1100071 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial belinostat RxCUI 1543543 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bicalutamide RxCUI 83008 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cabozantinib RxCUI 1363268 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial calcitriol RxCUI 1894 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cannabidiol RxCUI 2045371 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial celecoxib RxCUI 140587 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor103
collaborator3
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.